Loading...

Varnavas Mouchlis

TitleAssistant Project Scientist
InstitutionUniversity of California San Diego
DepartmentPharmacology
Address9500 Gilman Drive #0601
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Mouchlis V, Chen Y, McCammon JA, Dennis EA. Membrane Allostery and Unique Hydrophobic Sites Promote Enzyme Substrate Specificity. J Am Chem Soc. 2018 Mar 07; 140(9):3285-3291. PMID: 29342349.
      View in: PubMed
    2. Vasquez AM, Mouchlis V, Dennis EA. Review of four major distinct types of human phospholipase A2. Adv Biol Regul. 2018 Jan; 67:212-218. PMID: 29248300.
      View in: PubMed
    3. Kokotou MG, Galiatsatou G, Magrioti V, Koutoulogenis G, Barbayianni E, Limnios D, Mouchlis V, Satpathy B, Navratil A, Dennis EA, Kokotos G. 2-Oxoesters: A Novel Class of Potent and Selective Inhibitors of Cytosolic Group IVA Phospholipase A2. Sci Rep. 2017 Aug 01; 7(1):7025. PMID: 28765606.
      View in: PubMed
    4. Smyrniotou A, Kokotou MG, Mouchlis V, Barbayianni E, Kokotos G, Dennis EA, Constantinou-Kokotou V. 2-Oxoamides based on dipeptides as selective calcium-independent phospholipase A2 inhibitors. Bioorg Med Chem. 2017 02 01; 25(3):926-940. PMID: 28034646.
      View in: PubMed
    5. Antonopoulou G, Magrioti V, Kokotou MG, Nikolaou A, Barbayianni E, Mouchlis V, Dennis EA, Kokotos G. 2-Oxoamide inhibitors of cytosolic group IVA phospholipase A2 with reduced lipophilicity. Bioorg Med Chem. 2016 10 01; 24(19):4544-4554. PMID: 27522578; PMCID: PMC5014611 [Available on 10/01/17].
    6. Mouchlis V, Morisseau C, Hammock BD, Li S, McCammon JA, Dennis EA. Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A2. Bioorg Med Chem. 2016 10 15; 24(20):4801-4811. PMID: 27320659.
      View in: PubMed
    7. Mouchlis V, Limnios D, Kokotou MG, Barbayianni E, Kokotos G, McCammon JA, Dennis EA. Development of Potent and Selective Inhibitors for Group VIA Calcium-Independent Phospholipase A2 Guided by Molecular Dynamics and Structure-Activity Relationships. J Med Chem. 2016 05 12; 59(9):4403-14. PMID: 27087127; PMCID: PMC4946799 [Available on 05/12/17].
    8. Mouchlis V, Dennis EA. Membrane and inhibitor interactions of intracellular phospholipases A2. Adv Biol Regul. 2016 05; 61:17-24. PMID: 26774606; PMCID: PMC4884535 [Available on 05/01/17].
    9. Mouchlis V, Bucher D, McCammon JA, Dennis EA. Membranes serve as allosteric activators of phospholipase A2, enabling it to extract, bind, and hydrolyze phospholipid substrates. Proc Natl Acad Sci U S A. 2015 Feb 10; 112(6):E516-25. PMID: 25624474; PMCID: PMC4330758.
    10. Bucher D, Hsu YH, Mouchlis V, Dennis EA, McCammon JA. Insertion of the Ca²?-independent phospholipase A2 into a phospholipid bilayer via coarse-grained and atomistic molecular dynamics simulations. PLoS Comput Biol. 2013; 9(7):e1003156. PMID: 23935474; PMCID: PMC3723492.
    11. Zhang L, Sedykh A, Tripathi A, Zhu H, Afantitis A, Mouchlis V, Melagraki G, Rusyn I, Tropsha A. Identification of putative estrogen receptor-mediated endocrine disrupting chemicals using QSAR- and structure-based virtual screening approaches. Toxicol Appl Pharmacol. 2013 Oct 01; 272(1):67-76. PMID: 23707773; PMCID: PMC3775906.
    12. Mouchlis V, Melagraki G, Mavromoustakos T, Kollias G, Afantitis A. Molecular modeling on pyrimidine-urea inhibitors of TNF-a production: an integrated approach using a combination of molecular docking, classification techniques, and 3D-QSAR CoMSIA. J Chem Inf Model. 2012 Mar 26; 52(3):711-23. PMID: 22360289.
      View in: PubMed
    13. Mouchlis V, Michopoulou V, Constantinou-Kokotou V, Mavromoustakos T, Dennis EA, Kokotos G. Binding conformation of 2-oxoamide inhibitors to group IVA cytosolic phospholipase A2 determined by molecular docking combined with molecular dynamics. J Chem Inf Model. 2012 Jan 23; 52(1):243-54. PMID: 22196172; PMCID: PMC3265118.
    14. Tzoupis H, Leonis G, Durdagi S, Mouchlis V, Mavromoustakos T, Papadopoulos MG. Binding of novel fullerene inhibitors to HIV-1 protease: insight through molecular dynamics and molecular mechanics Poisson-Boltzmann surface area calculations. J Comput Aided Mol Des. 2011 Oct; 25(10):959-76. PMID: 21969102.
      View in: PubMed
    15. Mouchlis V, Magrioti V, Barbayianni E, Cermak N, Oslund RC, Mavromoustakos TM, Gelb MH, Kokotos G. Inhibition of secreted phospholipases A2 by 2-oxoamides based on a-amino acids: Synthesis, in vitro evaluation and molecular docking calculations. Bioorg Med Chem. 2011 Jan 15; 19(2):735-43. PMID: 21216150; PMCID: PMC3050527.
    16. Mouchlis V, Mavromoustakos TM, Kokotos G. Molecular docking and 3D-QSAR CoMFA studies on indole inhibitors of GIIA secreted phospholipase A(2). J Chem Inf Model. 2010 Sep 27; 50(9):1589-601. PMID: 20795712.
      View in: PubMed
    17. Mouchlis V, Mavromoustakos TM, Kokotos G. Design of new secreted phospholipase A2 inhibitors based on docking calculations by modifying the pharmacophore segments of the FPL67047XX inhibitor. J Comput Aided Mol Des. 2010 Feb; 24(2):107-15. PMID: 20130961.
      View in: PubMed